drugset / Trial / NCT00844298
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving nilotinib together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving nilotinib together with combination chemotherapy works in treating patients with newly diagnosed acute lymphoblastic leukemia.
Timeline
- Start
- 2009-01
- Primary completion
- 2012-06
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nilotinib | Small molecule | 400 mg | Oral |
| Background | Cytarabine | Small molecule | 2000 mg/m2 | Intravenous |
| Background | Daunorubicin | Small molecule | 45 mg/m2 | Intravenous |
| Background | Daunorubicin | Small molecule | 90 mg/m2 | Intravenous |
| Background | Etoposide | Small molecule | 150 mg/m2 | Intravenous |
| Background | Leucovorin | Small molecule | 50 mg/m2 | Intravenous |
| Background | Methotrexate | Small molecule | 60 mg/m2 | Intravenous |
| Background | Prednisolone | Other / unclassified | 60 mg/m2 | Oral |
| Background | Vincristine | Small molecule | 2 mg | Intravenous |